RAPT Therapeutics Reports First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
May 9, 2024 4:03 PM EDTGuggenheim analyst Yatin Suneja downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral.
The analyst comments "Key takeaways from our call with RAPT mgmt. include: (1) database cleaning is underway for both atopic dermatitis and asthma studies of RPT-193 (oral CCR4 blocker; recall that in Feb 2024, both clinical studies were put on... More
